Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in NRSN held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | Yorkville Advisors Global, LP | 78K | $59K | -22.0% | 0.336% | 0.04% |
| 2 | Independent Advisor Alliance | 50K | $38K | β | 0.215% | 0.00% |
| 3 | UBS Group AG | 49K | $37K | +59.0% | 0.211% | 0.00% |
| 4 | TWO SIGMA INVESTMENTS, LP | 44K | $34K | -13.8% | 0.191% | 0.00% |
| 5 | MEITAV DASH INVESTMENTS LTD | 40K | $30K | 0.0% | 0.172% | 0.00% |
| 6 | JANE STREET GROUP, LLC | 29K | $22K | β | 0.123% | 0.00% |
| 7 | COMMONWEALTH EQUITY SERVICES, LLC | 23K | $17K | 0.0% | 0.098% | 0.00% |
| 8 | PNC FINANCIAL SERVICES GROUP, INC. | 21K | $16K | β | 0.091% | 0.00% |
| 9 | Pathstone Holdings, LLC | 17K | $12K | 0.0% | 0.071% | 0.00% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 16K | $12K | 0.0% | 0.068% | 0.00% |
| 11 | Creative Planning | 12K | $9K | 0.0% | 0.051% | 0.00% |
| 12 | JONES FINANCIAL COMPANIES LLLP | 1K | $731 | 0.0% | 0.004% | 0.00% |
| 13 | SBI Securities Co., Ltd. | 265 | $200 | -81.8% | 0.001% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in NRSN β a direct measure of their conviction.
Filings activity in NRSN during Q1 2026, grouped by how each filer changed its position.
Institutions that opened a new NRSN position in Q1 2026
Institutions that fully closed their NRSN position in Q1 2026
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 13 | +0.0% | 1.68% | +0.12 pp | $0M | +7.7% |
| Q4 2025 | 13 | +18% | 1.56% | 0.98 pp | $0M | 39% |
| Q3 2025 | 11 | 35% | 2.54% | 1.96 pp | $0M | 44% |
| Q2 2025 | 17 | +42% | 4.50% | +3.54 pp | $1M | +369% |
| Q1 2025 | 12 | 14% | 0.96% | 3.01 pp | $0M | 76% |
| Q4 2024 | 14 | +75% | 3.97% | +2.40 pp | $1M | +152% |
| Q3 2024 | 8 | +0.0% | 1.57% | 9.38 pp | $0M | 86% |
| Q2 2024 | 8 | β | 10.95% | β | $2M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Latest Form 4 transactions by company officers and directors. Insider buys are widely viewed as the highest-conviction signal because executives are risking personal capital.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 16, 2026 | Eisenberg Or | Buy | 250K | $0.80 | $200K |
| Jun 16, 2026 | Ben-Noon Alon | Buy | 250K | $0.80 | $200K |
Quick answers to the most common questions about buying NRSN stock.
Based on Q1 2026 13F filings, institutional ownership of NeuroSense Therapeutics Ltd. stands at 1.7%, held across 13 reporting institutions.
Yorkville Advisors Global, LP is the largest reported institutional holder of NRSN, with approximately 78,000 shares worth $0.00B as of Q1 2026.
Yes β 2 widely-followed marquee investors appear among the top 25 institutional holders of NRSN, including TWO SIGMA INVESTMENTS, LP, JANE STREET GROUP, LLC.
Our composite Smart Money Score for NRSN is 55 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
3 institutions opened new positions in NRSN during Q1 2026, while 3 fully exited. 1 added to existing positions and 9 trimmed.
NRSN institutional ownership rose by 0.12 percentage points quarter-over-quarter, with a net change of +0 holders.
The top 10 institutions account for 96.5% of all reported 13F value in NRSN, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
NeuroSense Therapeutics Ltd. (NRSN) Institutional Ownership